Additional Listing Archives - Advanced Medical Solutions

Application for Admission

AdMedSol — Wed, 10 Sep 2025 07:00:14 +0000

RNS Number : 6759Y

Advanced Medical Solutions Grp PLC

10 September 2025

Advanced Medical Solutions Group plc

(“AMS”, the “Company” or the “Group”)

Application for Admission

Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the world-leading specialist in tissue-healing technologies, announces that an application has been made to the London Stock Exchange for the block listing of securities in respect of a total of 10,400,000 ordinary shares of 5 pence each (“New Ordinary Shares”) to be admitted to trading on AIM. Following the admission of these Ordinary Shares, there will be no change to the Company’s current issued share capital, which consists of 219,330,534 Ordinary Shares with voting rights.

The block listing application relates to New Ordinary Shares to be issued from time to time pursuant to the exercise of share options under the Company’s existing schemes as follows:

Scheme	No. of New Ordinary Shares
Employee Share Purchase Plan (ESPP)	2,000,000
Company Share Option Plan (CSOP)	200,000
Unapproved Executive Share Option Scheme (ESOS)	200,000
Long-Term Incentive Plan (LTIP)	4,000,000
Group Share Option Plan (GSOP)	4,000,000

In addition to the above, application has been made for 2,000,000 New Ordinary Shares has been applied for under the Employee Share Purchase Plan, previously named the Deferred Share Bonus Scheme.

An application has been made with respect to a new Block Listing for the Group Share Option Plan of 4,000,000 New Ordinary Shares.

When issued, the New Ordinary Shares will be credited as fully paid and will rank pari passu in all respects with the existing ordinary shares of 5 pence each in the capital of Advanced Medical Solutions Group plc.

It is expected that admission will become effective for the Ordinary Shares on 15 September 2025.

– End –

For further information, please visit www.admedsol.com or contact:

Advanced Medical Solutions Group plc	Tel: +44 (0) 1606 545508
Chris Meredith, Chief Executive Officer Eddie Johnson, Chief Financial Officer Michael King, Investor Relations

Optimum Strategic Communications	Tel: +44 (0) 20 3709 5700
Mary Clark / Nick Bastin / Isabelle Abdou	AMS@optimumcomms.com

Investec Bank PLC (NOMAD & Broker)	Tel: +44 (0) 20 7597 5970
Gary Clarence / David Anderson

Berenberg (Joint Broker)	Tel: +44 (0) 20 3207 7800
Toby Flaux / Detlir Elezi / Yasmina Benchekroun

About Advanced Medical Solutions Group plc – see www.admedsol.com

AMS is a world-leading independent developer and manufacturer of innovative tissue-healing technology, focused on quality outcomes for patients and value for payers. AMS has a wide range of surgical products including tissue adhesives, sutures, haemostats, internal fixation devices and internal sealants, which it markets under its brands LiquiBand®, RESORBA®, LiquiBandFix8®, LIQUIFIX™, Peters Surgical, Ifabond, Vitalitec and Seal-G®. AMS also supplies wound care dressings such as silver alginates, alginates and foams through its ActivHeal® brand as well as under white label. Since 2019, the Group has made seven acquisitions: Sealantis, an Israeli developer of innovative internal sealants, Biomatlante, a French developer and manufacturer of surgical biomaterials, Raleigh, a leading UK coater and converter of woundcare and bio-diagnostics materials, AFS Medical, an Austrian specialist surgical business, Connexicon, an Irish tissue adhesives specialist, Syntacoll, a German specialist in collagen-based absorbable surgical implants and Peters Surgical, a global provider of specialty surgical sutures, mechanical haemostasis and internal cyanoacrylate devices.

AMS’s products, manufactured in the UK, Germany, France, the Netherlands, Thailand, India, the Czech Republic and Israel, are sold globally via a network of multinational or regional partners and distributors, as well as via AMS’s own direct sales forces in the UK, Germany, Austria, France, Poland, Benelux, India, the Czech Republic and Russia. The Group has R&D innovation hubs in the UK, Ireland, Germany, France and Israel. Established in 1991, the Group has more than 1,500 employees. For more information, please see www.admedsol.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

ALSBRGDCGXGDGUC

The post Application for Admission appeared first on Advanced Medical Solutions.

Application for Admission

AdMedSol — Tue, 06 Nov 2018 16:33:10 +0000

RNS Number : 5378G

Advanced Medical Solutions Grp PLC

06 November 2018

6 November 2018

Advanced Medical Solutions Group plc

(“AMS” or the “Group”)

Application for Admission

Advanced Medical Solutions Group plc (AIM: AMS), the surgical and advanced wound care specialist company, announces that an application has been made to the London Stock Exchange for the admission of a total of 10,176,713 ordinary shares of 5 pence each (the “Ordinary Shares”) to trading on AIM.

Further to the announcement on 31 August 2018 and following a full reconciliation of shares previously allotted, all of the Ordinary Shares to which this application relates have been previously issued and allotted under various employee share schemes. As a result, following the admission of these Ordinary Shares, there will be no change to the Group’s current issued share capital, which consists of 213,454,651 Ordinary Shares with voting rights.

It is expected that admission will become effective for the Ordinary Shares on 12 November 2018.

For further information, please visit www.admedsol.com or contact:

Advanced Medical Solutions Group plc	Tel: 44 (0) 1606 545508
Chris Meredith, Chief Executive Officer Mary Tavener, Chief Financial Officer

Consilium Strategic Communications	Tel: 44 (0) 20 3709 5700
Mary-Jane Elliott / Matthew Neal / Nicholas Brown / Olivia Manser	AMS@consiliumcomms.com

Investec Bank PLC (NOMAD & Broker)	Tel: 44 (0) 20 7597 5970
Daniel Adams / Patrick Robb / Gary Clarence

About Advanced Medical Solutions Group plc – see www.admedsol.com

AMS is a world-leading independent developer and manufacturer of innovative and technologically advanced products for the global surgical, wound care and wound closure markets, focused on quality outcomes for patients and value for payors. AMS has a wide range of products that include silver alginates, alginates, foams, tissue adhesives, sutures and haemostats, which it markets under its brands; ActivHeal®, LiquiBand® and RESORBA® as well as supplying under white label.

AMS’s products, manufactured out of two sites in the UK, one in the Netherlands, two in Germany and one in the Czech Republic, are sold in more than 75 countries via a network of multinational or regional partners and distributors, as well as via AMS’s own direct sales forces in the UK, Germany, the Czech Republic and Russia. Established in 1991, the Group has approximately 600 employees. For more information, please see www.admedsol.com.

END

ALSBLBDBIDGBGIL

The post Application for Admission appeared first on Advanced Medical Solutions.

Application for Admission

AdMedSol — Fri, 31 Aug 2018 16:08:36 +0000

RNS Number : 4660Z

Advanced Medical Solutions Grp PLC

31 August 2018

Advanced Medical Solutions Group plc

(“AMS” or the “Company” or the “Group”)

Application for Admission

Advanced Medical Solutions Group plc (AIM: AMS), the surgical and advanced wound care specialist company, announces that an application has been made to the London Stock Exchange for the admission of a total of 8,023,268 ordinary shares of 5 pence each (the “Ordinary Shares”) to trading on AIM.

All of the Ordinary Shares to which this application relates, have been previously issued and allotted under various employee share schemes. As a result, following the admission of these Ordinary Shares, there will be no change to the Company’s current issued share capital, which consists of 213,442,312 Ordinary Shares with voting rights.

Further, AMS announces that an application has been made to the London Stock Exchange for the block listing of securities in respect of a total of 4,476,264 ordinary shares of 5 pence each (the “New Ordinary Shares”) to be admitted to trading on AIM.

The block listing application relates to New Ordinary Shares to be issued from time to time pursuant to the exercise of share options under the Company’s existing schemes as follows:

Scheme	No. of New Ordinary Shares
Deferred Share Bonus Scheme	804,569
Enterprise Management Incentive Scheme	43,172
Company Share Option Plan	439,808
Unapproved Executive Share Option Scheme	1,477,329
Long Term Incentive Plan	1,224,399
Deferred Annual Bonus Scheme	486,987

It is expected that admission will become effective for the Ordinary Shares on 6 September 2018.

For further information, please visit www.admedsol.com or contact:

Advanced Medical Solutions Group plc	Tel: 44 (0) 1606 545508
Chris Meredith, Chief Executive Officer Mary Tavener, Chief Financial Officer

Consilium Strategic Communications	Tel: 44 (0) 20 3709 5700
Mary-Jane Elliott / Matthew Neal / Nicholas Brown / Olivia Manser	AMS@consiliumcomms.com

Investec Bank PLC (NOMAD & Broker)	Tel: 44 (0) 20 7597 5970
Daniel Adams / Patrick Robb / Gary Clarence

About Advanced Medical Solutions Group plc – see www.admedsol.com

END

ALSBUGDIXGXBGIB

The post Application for Admission appeared first on Advanced Medical Solutions.

Additional Listing

AdMedSol — Mon, 17 Oct 2011 10:42:39 +0000

RNS Number : 2884Q

Advanced Medical Solutions Grp PLC

17 October 2011

Advanced Medical Solutions Group plc (the “Company”)

Application for block admission

The Company announces that an application has been made to the London Stock Exchange for the block admission of 2,000,000 ordinary shares of 5 pence each (the “Shares”). Admission of the Shares is expected to take place on 18 October 2011.

The Shares will be issued from time to time pursuant to the exercise of share options under the Company’s Unapproved Executive Share Option Scheme, Enterprise Management Incentive Scheme, Company Share Option Plan, Long Term Incentive Plan and Deferred Share Bonus Scheme. They will be issued credited as fully paid and will rank pari passu with the existing Ordinary Shares of the Company.

For enquiries:

Advanced Medical Solutions Group plc +44 (0) 1606 545 508

Chris Meredith, Chief Executive Officer

Mary Tavener, Group Finance Director

Investec Investment Banking (NOMAD) +44 (0) 20 7597 5970

Daniel Adams

Gary Clarence

This information is provided by RNS

The company news service from the London Stock Exchange

END

LISGGGGCUUPGUBM

The post Additional Listing appeared first on Advanced Medical Solutions.

Additional Listing

AdMedSol — Thu, 30 Apr 2009 15:01:00 +0000

RNS Number : 5108R

Advanced Medical Solutions Grp PLC

30 April 2009

Advanced Medical Solutions Group plc (“AMS” or the “Group”)

Additional listing

The Board of AMS announces that an application has been made to the London Stock Exchange for the admission of 162,352 ordinary shares of 5p each (“Ordinary Shares”) to AIM. The new ordinary shares will rank pari passu with the existing Ordinary Shares in issue.

These shares will be allotted from time to time in accordance with the issue of shares under the Advanced Medical Solutions Group plc Deferred Share Bonus Plan.

It is expected that admission of the new ordinary shares will become effective on 6 May 2009.

For further information contact:

Advanced Medical Solutions Group plc

Mary Tavener, Finance Director

Tel: +44 (0) 1606 545508

This information is provided by RNS

The company news service from the London Stock Exchange

END

LISWUUUUCUPBGCU

The post Additional Listing appeared first on Advanced Medical Solutions.